Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway

被引:85
作者
Wu, Lujin [1 ,2 ]
Wang, Ke [3 ]
Wang, Wei [1 ,2 ]
Wen, Zheng [1 ,2 ]
Wang, Peihua [1 ,2 ]
Liu, Lei [1 ,2 ]
Wang, Dao Wen [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Internal Med,Div Cardiol, Wuhan, Hubei, Peoples R China
[2] Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Wuhan, Hubei, Peoples R China
[3] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Dept Neonatal Med, Wuhan, Peoples R China
关键词
apoptosis; DPP-4; GLP-1; lipotoxicity cardiomyopathy; PPAR alpha; MYOCARDIAL SUBSTRATE METABOLISM; ACTIVATED RECEPTOR-ALPHA; OXIDATIVE STRESS; RHO-KINASE; APOPTOSIS; HEART; DYSFUNCTION; INHIBITORS; EXPRESSION; PROTECTS;
D O I
10.1111/acel.12763
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Lipotoxicity cardiomyopathy is the result of excessive accumulation and oxidation of toxic lipids in the heart. It is a major threat to patients with diabetes. Glucagon-like peptide-1 (GLP-1) has aroused considerable interest as a novel therapeutic target for diabetes mellitus because it stimulates insulin secretion. Here, we investigated the effects and mechanisms of the GLP-1 analog exendin-4 and the dipeptidyl peptidase-4 inhibitor saxagliptin on cardiac lipid metabolism in diabetic mice (DM). The increased myocardial lipid accumulation, oxidative stress, apoptosis, and cardiac remodeling and dysfunction induced in DM by low streptozotocin doses and high-fat diets were significantly reversed by exendin-4 and saxagliptin treatments for 8 weeks. We found that exendin-4 inhibited abnormal activation of the (PPAR alpha)-CD36 pathway by stimulating protein kinase A (PKA) but suppressing the Rho-associated protein kinase (ROCK) pathway in DM hearts, palmitic acid (PA)-treated rat h9c2 cardiomyocytes (CMs), and isolated adult mouse CMs. Cardioprotection in DM mediated by exendin-4 was abolished by combination therapy with the PPAR alpha agonist wy-14643 but mimicked by PPAR alpha gene deficiency. Therefore, the PPAR alpha pathway accounted for the effects of exendin-4. This conclusion was confirmed in cardiac-restricted overexpression of PPAR alpha mediated by adeno-associated virus serotype-9 containing a cardiac troponin T promoter. Our results provide the first direct evidence that GLP-1 protects cardiac function by inhibiting the ROCK/PPAR alpha pathway, thereby ameliorating lipotoxicity in diabetic cardiomyopathy.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Substrate-Specific Derangements in Mitochondrial Metabolism and Redox Balance in the Atrium of the Type 2 Diabetic Human Heart
    Anderson, Ethan J.
    Kypson, Alan P.
    Rodriguez, Evelio
    Anderson, Curtis A.
    Lehr, Eric J.
    Neufer, P. Darrell
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (20) : 1891 - 1898
  • [2] CD36 inhibition prevents lipid accumulation and contractile dysfunction in rat cardiomyocytes
    Angin, Yeliz
    Steinbusch, Laura K. M.
    Simons, Peter J.
    Greulich, Sabrina
    Hoebers, Nicole T. H.
    Douma, Kim
    van Zandvoort, Marc A. M. J.
    Coumans, Will A.
    Wijnen, Wino
    Diamant, Michaela
    Ouwens, D. Margriet
    Glatz, Jan F. C.
    Luiken, Joost J. F. P.
    [J]. BIOCHEMICAL JOURNAL, 2012, 448 : 43 - 53
  • [3] Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
    Ban, Kiwon
    Noyan-Ashraf, M. Hossein
    Hoefer, Judith
    Bolz, Steffen-Sebastian
    Drucker, Daniel J.
    Husain, Mansoor
    [J]. CIRCULATION, 2008, 117 (18) : 2340 - 2350
  • [4] Preferential Oxidation of Triacylglyceride-Derived Fatty Acids in Heart Is Augmented by the Nuclear Receptor PPARα
    Banke, Natasha H.
    Wende, Adam R.
    Leone, Teresa C.
    O'Donnell, J. Michael
    Abel, E. Dale
    Kelly, Daniel P.
    Lewandowski, E. Douglas
    [J]. CIRCULATION RESEARCH, 2010, 107 (02) : 233 - 241
  • [5] Targeting Apoptosis in the Heart of Streptozotocin-Induced Diabetic Rats
    Baraka, Azza
    AbdelGawad, Hala
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2010, 15 (02) : 175 - 181
  • [6] Diabetic cardiomyopathy and metabolic remodeling of the heart
    Battiprolu, Pavan K.
    Lopez-Crisosto, Camila
    Wang, Zhao V.
    Nemchenko, Andriy
    Lavandero, Sergio
    Hill, Joseph A.
    [J]. LIFE SCIENCES, 2013, 92 (11) : 609 - 615
  • [7] Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease
    Bernardi, Stella
    Michelli, Andrea
    Zuolo, Giulia
    Candido, Riccardo
    Fabris, Bruno
    [J]. JOURNAL OF DIABETES RESEARCH, 2016, 2016
  • [8] Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity
    Boudina, S
    Sena, S
    O'Neill, BT
    Tathireddy, P
    Young, ME
    Abel, ED
    [J]. CIRCULATION, 2005, 112 (17) : 2686 - 2695
  • [9] Diabetic cardiomyopathy revisited
    Boudina, Sihem
    Abel, E. Dale
    [J]. CIRCULATION, 2007, 115 (25) : 3213 - 3223
  • [10] A role for peroxisome proliferator-activated receptor α (PPARα) in the control of cardiac malonyl-CoA levels -: Reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARα are associated with higher concentrations of maloncyl-CoA and reduced expression of malonyl-CoA decarboxlase
    Campbell, FM
    Kozak, R
    Wagner, A
    Altarejos, JY
    Dyck, JRB
    Belke, DD
    Severson, DL
    Kelly, DP
    Lopaschuk, GD
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (06) : 4098 - 4103